european medicines agency news - Search News

European Committee Takes a Second Look at Alzheimer's Drug

The Associated Press - Busines… · 2d

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting the drug.

Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved.

Medical Xpress · 3d

European watchdog partially approves new Alzheimer's drug

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.

13d

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

12don MSN

Is Novo Nordisk A/S (NVO) The Best European Stock To Buy According to Hedge Funds?

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

2d

Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early Alzheimer's Disease

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

Aurobindo Pharma Subsidiary Receives GMP From European Medicines Agency For Biosimilars Facility

CuraTeQ Biologics' EMA GMP certification marks a key milestone in Aurobindo Pharma's expansion into biosimilars, with three ...

11d

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

2d

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

3d

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results